| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |